nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Pentagastrin—Goserelin—breast cancer	0.424	1	CrCrCtD
Carfilzomib—ABCB1—breast cancer	0.0877	1	CbGaD
Carfilzomib—ABCB1—Toremifene—breast cancer	0.0268	0.223	CbGbCtD
Carfilzomib—ABCB1—Lapatinib—breast cancer	0.0195	0.162	CbGbCtD
Carfilzomib—ABCB1—Vinorelbine—breast cancer	0.0108	0.0901	CbGbCtD
Carfilzomib—ABCB1—Tamoxifen—breast cancer	0.00978	0.0813	CbGbCtD
Carfilzomib—ABCB1—Mitoxantrone—breast cancer	0.00954	0.0793	CbGbCtD
Carfilzomib—ABCB1—Gemcitabine—breast cancer	0.00843	0.0701	CbGbCtD
Carfilzomib—ABCB1—Paclitaxel—breast cancer	0.00761	0.0633	CbGbCtD
Carfilzomib—ABCB1—Irinotecan—breast cancer	0.00751	0.0624	CbGbCtD
Carfilzomib—ABCB1—Vinblastine—breast cancer	0.00668	0.0555	CbGbCtD
Carfilzomib—ABCB1—Docetaxel—breast cancer	0.0055	0.0458	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—breast cancer	0.0041	0.0341	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—breast cancer	0.00397	0.033	CbGbCtD
Carfilzomib—PSMB8—nipple—breast cancer	0.0025	0.0387	CbGeAlD
Carfilzomib—PSMB2—mammary gland—breast cancer	0.00228	0.0353	CbGeAlD
Carfilzomib—PSMB5—nipple—breast cancer	0.00221	0.0342	CbGeAlD
Carfilzomib—PSMB10—adipose tissue—breast cancer	0.00211	0.0327	CbGeAlD
Carfilzomib—PSMB10—female reproductive system—breast cancer	0.00194	0.03	CbGeAlD
Carfilzomib—PSMB1—nipple—breast cancer	0.00193	0.0299	CbGeAlD
Carfilzomib—PSMB10—adrenal gland—breast cancer	0.00189	0.0293	CbGeAlD
Carfilzomib—PSMB2—nipple—breast cancer	0.00188	0.0292	CbGeAlD
Carfilzomib—PSMB10—female gonad—breast cancer	0.00177	0.0273	CbGeAlD
Carfilzomib—PSMB10—endocrine gland—breast cancer	0.00164	0.0254	CbGeAlD
Carfilzomib—PSMB1—embryo—breast cancer	0.00159	0.0247	CbGeAlD
Carfilzomib—PSMB2—embryo—breast cancer	0.00155	0.0241	CbGeAlD
Carfilzomib—PSMB8—endometrium—breast cancer	0.00151	0.0234	CbGeAlD
Carfilzomib—PSMB8—pituitary gland—breast cancer	0.00137	0.0212	CbGeAlD
Carfilzomib—PSMB8—adipose tissue—breast cancer	0.00136	0.0211	CbGeAlD
Carfilzomib—PSMB5—endometrium—breast cancer	0.00133	0.0206	CbGeAlD
Carfilzomib—PSMB1—skin of body—breast cancer	0.00124	0.0191	CbGeAlD
Carfilzomib—PSMB5—uterus—breast cancer	0.00123	0.019	CbGeAlD
Carfilzomib—PSMB8—adrenal gland—breast cancer	0.00122	0.0189	CbGeAlD
Carfilzomib—PSMB5—pituitary gland—breast cancer	0.00121	0.0187	CbGeAlD
Carfilzomib—PSMB2—skin of body—breast cancer	0.00121	0.0187	CbGeAlD
Carfilzomib—PSMB5—adipose tissue—breast cancer	0.0012	0.0186	CbGeAlD
Carfilzomib—PSMB8—bone marrow—breast cancer	0.00118	0.0183	CbGeAlD
Carfilzomib—PSMB1—endometrium—breast cancer	0.00117	0.018	CbGeAlD
Carfilzomib—PSMB8—female gonad—breast cancer	0.00114	0.0176	CbGeAlD
Carfilzomib—PSMB2—endometrium—breast cancer	0.00114	0.0176	CbGeAlD
Carfilzomib—PSMB10—lymph node—breast cancer	0.00114	0.0176	CbGeAlD
Carfilzomib—PSMB5—adrenal gland—breast cancer	0.00108	0.0167	CbGeAlD
Carfilzomib—PSMB1—uterus—breast cancer	0.00107	0.0166	CbGeAlD
Carfilzomib—PSMB1—pituitary gland—breast cancer	0.00105	0.0163	CbGeAlD
Carfilzomib—PSMB1—adipose tissue—breast cancer	0.00105	0.0163	CbGeAlD
Carfilzomib—PSMB2—uterus—breast cancer	0.00105	0.0162	CbGeAlD
Carfilzomib—PSMB5—bone marrow—breast cancer	0.00104	0.0161	CbGeAlD
Carfilzomib—PSMB2—pituitary gland—breast cancer	0.00103	0.0159	CbGeAlD
Carfilzomib—PSMB2—adipose tissue—breast cancer	0.00102	0.0159	CbGeAlD
Carfilzomib—PSMB5—female gonad—breast cancer	0.001	0.0156	CbGeAlD
Carfilzomib—PSMB1—female reproductive system—breast cancer	0.000965	0.015	CbGeAlD
Carfilzomib—PSMB1—adrenal gland—breast cancer	0.000942	0.0146	CbGeAlD
Carfilzomib—PSMB2—female reproductive system—breast cancer	0.000942	0.0146	CbGeAlD
Carfilzomib—PSMB2—adrenal gland—breast cancer	0.000919	0.0142	CbGeAlD
Carfilzomib—PSMB1—bone marrow—breast cancer	0.000911	0.0141	CbGeAlD
Carfilzomib—PSMB2—bone marrow—breast cancer	0.000889	0.0138	CbGeAlD
Carfilzomib—PSMB1—female gonad—breast cancer	0.000878	0.0136	CbGeAlD
Carfilzomib—PSMB2—female gonad—breast cancer	0.000857	0.0133	CbGeAlD
Carfilzomib—PSMB1—endocrine gland—breast cancer	0.000817	0.0127	CbGeAlD
Carfilzomib—PSMB2—endocrine gland—breast cancer	0.000797	0.0123	CbGeAlD
Carfilzomib—Ritonavir—SLCO1B1—breast cancer	0.000771	0.218	CrCbGaD
Carfilzomib—PSMB8—lymph node—breast cancer	0.000731	0.0113	CbGeAlD
Carfilzomib—Pentagastrin—BCHE—breast cancer	0.0007	0.197	CrCbGaD
Carfilzomib—PSMB5—lymph node—breast cancer	0.000646	0.01	CbGeAlD
Carfilzomib—Ritonavir—ABCC1—breast cancer	0.000636	0.18	CrCbGaD
Carfilzomib—PSMB1—lymph node—breast cancer	0.000565	0.00875	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vinorelbine—breast cancer	0.000563	0.166	CbGdCrCtD
Carfilzomib—PSMB2—lymph node—breast cancer	0.000551	0.00853	CbGeAlD
Carfilzomib—PSMB10—Tamoxifen—Toremifene—breast cancer	0.000457	0.135	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Fluoxymesterone—breast cancer	0.00036	0.106	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Fluoxymesterone—breast cancer	0.00036	0.106	CbGdCrCtD
Carfilzomib—Ritonavir—ABCG2—breast cancer	0.000335	0.0947	CrCbGaD
Carfilzomib—PSMB2—Azacitidine—Gemcitabine—breast cancer	0.000281	0.0827	CbGdCrCtD
Carfilzomib—PSMB8—Vincristine—Vinorelbine—breast cancer	0.000267	0.0787	CbGdCrCtD
Carfilzomib—PSMB8—Vinorelbine—Vinblastine—breast cancer	0.00025	0.0736	CbGdCrCtD
Carfilzomib—ABCB1—embryo—breast cancer	0.000237	0.00368	CbGeAlD
Carfilzomib—Lopinavir—CYP2D6—breast cancer	0.000233	0.0656	CrCbGaD
Carfilzomib—PSMB8—Vincristine—Vinblastine—breast cancer	0.000214	0.0629	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Fluoxymesterone—breast cancer	0.000203	0.0599	CbGdCrCtD
Carfilzomib—Lopinavir—CYP3A4—breast cancer	0.000199	0.0563	CrCbGaD
Carfilzomib—Ritonavir—CYP2D6—breast cancer	0.000196	0.0552	CrCbGaD
Carfilzomib—ABCB1—epithelium—breast cancer	0.000194	0.003	CbGeAlD
Carfilzomib—ABCB1—endometrium—breast cancer	0.000174	0.00269	CbGeAlD
Carfilzomib—Ritonavir—CYP3A4—breast cancer	0.000168	0.0473	CrCbGaD
Carfilzomib—Lopinavir—ABCB1—breast cancer	0.000166	0.0469	CrCbGaD
Carfilzomib—ABCB1—uterus—breast cancer	0.00016	0.00248	CbGeAlD
Carfilzomib—ABCB1—pituitary gland—breast cancer	0.000157	0.00243	CbGeAlD
Carfilzomib—ABCB1—adipose tissue—breast cancer	0.000157	0.00242	CbGeAlD
Carfilzomib—PSMB8—Testosterone Propionate—Fluoxymesterone—breast cancer	0.000156	0.0461	CbGdCrCtD
Carfilzomib—ABCB1—female reproductive system—breast cancer	0.000144	0.00223	CbGeAlD
Carfilzomib—ABCB1—adrenal gland—breast cancer	0.00014	0.00217	CbGeAlD
Carfilzomib—Ritonavir—ABCB1—breast cancer	0.00014	0.0394	CrCbGaD
Carfilzomib—ABCB1—bone marrow—breast cancer	0.000136	0.0021	CbGeAlD
Carfilzomib—ABCB1—female gonad—breast cancer	0.000131	0.00203	CbGeAlD
Carfilzomib—ABCB1—endocrine gland—breast cancer	0.000122	0.00189	CbGeAlD
Carfilzomib—PSMB8—Norethindrone—Fluoxymesterone—breast cancer	0.000117	0.0345	CbGdCrCtD
Carfilzomib—ABCB1—lymph node—breast cancer	8.42e-05	0.0013	CbGeAlD
Carfilzomib—PSMB8—Dexamethasone—Fluoxymesterone—breast cancer	8.3e-05	0.0245	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Fluoxymesterone—breast cancer	8.3e-05	0.0245	CbGdCrCtD
Carfilzomib—Anorexia—Fluorouracil—breast cancer	7.41e-05	0.000504	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mitoxantrone—breast cancer	7.4e-05	0.000503	CcSEcCtD
Carfilzomib—Insomnia—Irinotecan—breast cancer	7.34e-05	0.000499	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—breast cancer	7.33e-05	0.000498	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—breast cancer	7.32e-05	0.000498	CcSEcCtD
Carfilzomib—Vomiting—Tamoxifen—breast cancer	7.32e-05	0.000497	CcSEcCtD
Carfilzomib—Dizziness—Goserelin—breast cancer	7.27e-05	0.000494	CcSEcCtD
Carfilzomib—Leukopenia—Paclitaxel—breast cancer	7.26e-05	0.000494	CcSEcCtD
Carfilzomib—Dyspnoea—Irinotecan—breast cancer	7.24e-05	0.000492	CcSEcCtD
Carfilzomib—Dyspnoea—Mitoxantrone—breast cancer	7.24e-05	0.000492	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—breast cancer	7.22e-05	0.000491	CcSEcCtD
Carfilzomib—Headache—Tamoxifen—breast cancer	7.21e-05	0.00049	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Gemcitabine—breast cancer	7.21e-05	0.00049	CcSEcCtD
Carfilzomib—Vomiting—Melphalan—breast cancer	7.16e-05	0.000487	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—breast cancer	7.15e-05	0.000487	CcSEcCtD
Carfilzomib—Insomnia—Gemcitabine—breast cancer	7.15e-05	0.000486	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—breast cancer	7.13e-05	0.000485	CcSEcCtD
Carfilzomib—Cardiac disorder—Capecitabine—breast cancer	7.1e-05	0.000483	CcSEcCtD
Carfilzomib—Chills—Docetaxel—breast cancer	7.09e-05	0.000482	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fluorouracil—breast cancer	7.08e-05	0.000482	CcSEcCtD
Carfilzomib—Cough—Paclitaxel—breast cancer	7.08e-05	0.000481	CcSEcCtD
Carfilzomib—Asthenia—Vinorelbine—breast cancer	7.06e-05	0.00048	CcSEcCtD
Carfilzomib—Decreased appetite—Mitoxantrone—breast cancer	7.06e-05	0.00048	CcSEcCtD
Carfilzomib—Decreased appetite—Irinotecan—breast cancer	7.06e-05	0.00048	CcSEcCtD
Carfilzomib—Dyspnoea—Gemcitabine—breast cancer	7.05e-05	0.000479	CcSEcCtD
Carfilzomib—Nausea—Vinblastine—breast cancer	7.04e-05	0.000478	CcSEcCtD
Carfilzomib—Insomnia—Fluorouracil—breast cancer	7.03e-05	0.000478	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—breast cancer	7.01e-05	0.000477	CcSEcCtD
Carfilzomib—Hypertension—Paclitaxel—breast cancer	7e-05	0.000476	CcSEcCtD
Carfilzomib—Fatigue—Mitoxantrone—breast cancer	7e-05	0.000476	CcSEcCtD
Carfilzomib—Fatigue—Irinotecan—breast cancer	7e-05	0.000476	CcSEcCtD
Carfilzomib—Vomiting—Goserelin—breast cancer	6.99e-05	0.000475	CcSEcCtD
Carfilzomib—Pain—Mitoxantrone—breast cancer	6.94e-05	0.000472	CcSEcCtD
Carfilzomib—Constipation—Mitoxantrone—breast cancer	6.94e-05	0.000472	CcSEcCtD
Carfilzomib—Pain—Irinotecan—breast cancer	6.94e-05	0.000472	CcSEcCtD
Carfilzomib—Constipation—Irinotecan—breast cancer	6.94e-05	0.000472	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—breast cancer	6.94e-05	0.000472	CcSEcCtD
Carfilzomib—Dyspnoea—Fluorouracil—breast cancer	6.93e-05	0.000471	CcSEcCtD
Carfilzomib—Arthralgia—Paclitaxel—breast cancer	6.91e-05	0.00047	CcSEcCtD
Carfilzomib—Headache—Goserelin—breast cancer	6.89e-05	0.000468	CcSEcCtD
Carfilzomib—Decreased appetite—Gemcitabine—breast cancer	6.87e-05	0.000467	CcSEcCtD
Carfilzomib—Chills—Capecitabine—breast cancer	6.86e-05	0.000467	CcSEcCtD
Carfilzomib—Nausea—Tamoxifen—breast cancer	6.84e-05	0.000465	CcSEcCtD
Carfilzomib—Fatigue—Gemcitabine—breast cancer	6.82e-05	0.000464	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—breast cancer	6.78e-05	0.000461	CcSEcCtD
Carfilzomib—Constipation—Gemcitabine—breast cancer	6.76e-05	0.00046	CcSEcCtD
Carfilzomib—Pain—Gemcitabine—breast cancer	6.76e-05	0.00046	CcSEcCtD
Carfilzomib—Decreased appetite—Fluorouracil—breast cancer	6.76e-05	0.00046	CcSEcCtD
Carfilzomib—Asthenia—Thiotepa—breast cancer	6.75e-05	0.000459	CcSEcCtD
Carfilzomib—Diarrhoea—Vinorelbine—breast cancer	6.74e-05	0.000458	CcSEcCtD
Carfilzomib—Nausea—Melphalan—breast cancer	6.69e-05	0.000455	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—breast cancer	6.68e-05	0.000454	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—breast cancer	6.65e-05	0.000452	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—breast cancer	6.65e-05	0.000452	CcSEcCtD
Carfilzomib—Pain—Fluorouracil—breast cancer	6.65e-05	0.000452	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—breast cancer	6.61e-05	0.00045	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—breast cancer	6.61e-05	0.00045	CcSEcCtD
Carfilzomib—Infection—Paclitaxel—breast cancer	6.58e-05	0.000447	CcSEcCtD
Carfilzomib—Nausea—Goserelin—breast cancer	6.53e-05	0.000444	CcSEcCtD
Carfilzomib—Dizziness—Vinorelbine—breast cancer	6.51e-05	0.000443	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—breast cancer	6.49e-05	0.000441	CcSEcCtD
Carfilzomib—Thrombocytopenia—Paclitaxel—breast cancer	6.48e-05	0.000441	CcSEcCtD
Carfilzomib—Back pain—Capecitabine—breast cancer	6.44e-05	0.000438	CcSEcCtD
Carfilzomib—Diarrhoea—Thiotepa—breast cancer	6.43e-05	0.000437	CcSEcCtD
Carfilzomib—Body temperature increased—Mitoxantrone—breast cancer	6.42e-05	0.000436	CcSEcCtD
Carfilzomib—Body temperature increased—Irinotecan—breast cancer	6.42e-05	0.000436	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—breast cancer	6.42e-05	0.000436	CcSEcCtD
Carfilzomib—Muscle spasms—Capecitabine—breast cancer	6.4e-05	0.000435	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—breast cancer	6.38e-05	0.000434	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—breast cancer	6.36e-05	0.000432	CcSEcCtD
Carfilzomib—Anorexia—Paclitaxel—breast cancer	6.31e-05	0.000429	CcSEcCtD
Carfilzomib—Vomiting—Vinorelbine—breast cancer	6.26e-05	0.000426	CcSEcCtD
Carfilzomib—Body temperature increased—Gemcitabine—breast cancer	6.25e-05	0.000425	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—breast cancer	6.23e-05	0.000424	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—breast cancer	6.22e-05	0.000423	CcSEcCtD
Carfilzomib—Dizziness—Thiotepa—breast cancer	6.22e-05	0.000423	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—breast cancer	6.19e-05	0.000421	CcSEcCtD
Carfilzomib—Headache—Vinorelbine—breast cancer	6.17e-05	0.000419	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—breast cancer	6.16e-05	0.000419	CcSEcCtD
Carfilzomib—Anaemia—Capecitabine—breast cancer	6.15e-05	0.000418	CcSEcCtD
Carfilzomib—Body temperature increased—Fluorouracil—breast cancer	6.15e-05	0.000418	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Paclitaxel—breast cancer	6.03e-05	0.00041	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—breast cancer	6e-05	0.000408	CcSEcCtD
Carfilzomib—Cough—Docetaxel—breast cancer	6e-05	0.000408	CcSEcCtD
Carfilzomib—Insomnia—Paclitaxel—breast cancer	5.99e-05	0.000407	CcSEcCtD
Carfilzomib—Vomiting—Thiotepa—breast cancer	5.98e-05	0.000406	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—breast cancer	5.97e-05	0.000406	CcSEcCtD
Carfilzomib—Leukopenia—Capecitabine—breast cancer	5.96e-05	0.000405	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—breast cancer	5.94e-05	0.000404	CcSEcCtD
Carfilzomib—Dyspnoea—Paclitaxel—breast cancer	5.9e-05	0.000401	CcSEcCtD
Carfilzomib—Headache—Thiotepa—breast cancer	5.89e-05	0.0004	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—breast cancer	5.85e-05	0.000398	CcSEcCtD
Carfilzomib—Nausea—Vinorelbine—breast cancer	5.85e-05	0.000398	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—breast cancer	5.83e-05	0.000397	CcSEcCtD
Carfilzomib—Asthenia—Mitoxantrone—breast cancer	5.82e-05	0.000396	CcSEcCtD
Carfilzomib—Asthenia—Irinotecan—breast cancer	5.82e-05	0.000396	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—breast cancer	5.82e-05	0.000396	CcSEcCtD
Carfilzomib—Cough—Capecitabine—breast cancer	5.81e-05	0.000395	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—breast cancer	5.76e-05	0.000392	CcSEcCtD
Carfilzomib—Decreased appetite—Paclitaxel—breast cancer	5.76e-05	0.000391	CcSEcCtD
Carfilzomib—Hypertension—Capecitabine—breast cancer	5.75e-05	0.000391	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—breast cancer	5.72e-05	0.000389	CcSEcCtD
Carfilzomib—Fatigue—Paclitaxel—breast cancer	5.71e-05	0.000388	CcSEcCtD
Carfilzomib—Asthenia—Gemcitabine—breast cancer	5.67e-05	0.000386	CcSEcCtD
Carfilzomib—Arthralgia—Capecitabine—breast cancer	5.67e-05	0.000385	CcSEcCtD
Carfilzomib—Constipation—Paclitaxel—breast cancer	5.66e-05	0.000385	CcSEcCtD
Carfilzomib—Pain—Paclitaxel—breast cancer	5.66e-05	0.000385	CcSEcCtD
Carfilzomib—Nausea—Thiotepa—breast cancer	5.58e-05	0.00038	CcSEcCtD
Carfilzomib—Infection—Docetaxel—breast cancer	5.58e-05	0.000379	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—breast cancer	5.56e-05	0.000378	CcSEcCtD
Carfilzomib—Diarrhoea—Irinotecan—breast cancer	5.55e-05	0.000378	CcSEcCtD
Carfilzomib—Diarrhoea—Mitoxantrone—breast cancer	5.55e-05	0.000378	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—breast cancer	5.52e-05	0.000376	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—breast cancer	5.49e-05	0.000374	CcSEcCtD
Carfilzomib—Diarrhoea—Gemcitabine—breast cancer	5.41e-05	0.000368	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—breast cancer	5.4e-05	0.000367	CcSEcCtD
Carfilzomib—Infection—Capecitabine—breast cancer	5.4e-05	0.000367	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—breast cancer	5.38e-05	0.000366	CcSEcCtD
Carfilzomib—Dizziness—Irinotecan—breast cancer	5.37e-05	0.000365	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—breast cancer	5.35e-05	0.000364	CcSEcCtD
Carfilzomib—Diarrhoea—Fluorouracil—breast cancer	5.32e-05	0.000362	CcSEcCtD
Carfilzomib—Thrombocytopenia—Capecitabine—breast cancer	5.32e-05	0.000362	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—breast cancer	5.3e-05	0.00036	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—breast cancer	5.28e-05	0.000359	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—breast cancer	5.25e-05	0.000357	CcSEcCtD
Carfilzomib—Body temperature increased—Paclitaxel—breast cancer	5.23e-05	0.000356	CcSEcCtD
Carfilzomib—Anorexia—Capecitabine—breast cancer	5.18e-05	0.000352	CcSEcCtD
Carfilzomib—Vomiting—Mitoxantrone—breast cancer	5.16e-05	0.000351	CcSEcCtD
Carfilzomib—Vomiting—Irinotecan—breast cancer	5.16e-05	0.000351	CcSEcCtD
Carfilzomib—Dizziness—Fluorouracil—breast cancer	5.14e-05	0.00035	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—breast cancer	5.11e-05	0.000348	CcSEcCtD
Carfilzomib—Chills—Methotrexate—breast cancer	5.11e-05	0.000347	CcSEcCtD
Carfilzomib—Headache—Irinotecan—breast cancer	5.09e-05	0.000346	CcSEcCtD
Carfilzomib—Headache—Mitoxantrone—breast cancer	5.09e-05	0.000346	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—breast cancer	5.08e-05	0.000345	CcSEcCtD
Carfilzomib—Vomiting—Gemcitabine—breast cancer	5.03e-05	0.000342	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—breast cancer	5e-05	0.00034	CcSEcCtD
Carfilzomib—Headache—Gemcitabine—breast cancer	4.95e-05	0.000337	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Capecitabine—breast cancer	4.95e-05	0.000337	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—breast cancer	4.94e-05	0.000336	CcSEcCtD
Carfilzomib—Vomiting—Fluorouracil—breast cancer	4.94e-05	0.000336	CcSEcCtD
Carfilzomib—Insomnia—Capecitabine—breast cancer	4.91e-05	0.000334	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—breast cancer	4.91e-05	0.000334	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—breast cancer	4.88e-05	0.000332	CcSEcCtD
Carfilzomib—Headache—Fluorouracil—breast cancer	4.87e-05	0.000331	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—breast cancer	4.86e-05	0.00033	CcSEcCtD
Carfilzomib—Dyspnoea—Capecitabine—breast cancer	4.84e-05	0.000329	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—breast cancer	4.84e-05	0.000329	CcSEcCtD
Carfilzomib—Nausea—Irinotecan—breast cancer	4.82e-05	0.000328	CcSEcCtD
Carfilzomib—Nausea—Mitoxantrone—breast cancer	4.82e-05	0.000328	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—breast cancer	4.8e-05	0.000326	CcSEcCtD
Carfilzomib—Pain—Docetaxel—breast cancer	4.8e-05	0.000326	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—breast cancer	4.79e-05	0.000326	CcSEcCtD
Carfilzomib—Chills—Epirubicin—breast cancer	4.78e-05	0.000325	CcSEcCtD
Carfilzomib—Asthenia—Paclitaxel—breast cancer	4.75e-05	0.000323	CcSEcCtD
Carfilzomib—Decreased appetite—Capecitabine—breast cancer	4.72e-05	0.000321	CcSEcCtD
Carfilzomib—Nausea—Gemcitabine—breast cancer	4.7e-05	0.000319	CcSEcCtD
Carfilzomib—Fatigue—Capecitabine—breast cancer	4.68e-05	0.000319	CcSEcCtD
Carfilzomib—Constipation—Capecitabine—breast cancer	4.65e-05	0.000316	CcSEcCtD
Carfilzomib—Pain—Capecitabine—breast cancer	4.65e-05	0.000316	CcSEcCtD
Carfilzomib—Nausea—Fluorouracil—breast cancer	4.62e-05	0.000314	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—breast cancer	4.58e-05	0.000311	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—breast cancer	4.58e-05	0.000311	CcSEcCtD
Carfilzomib—Diarrhoea—Paclitaxel—breast cancer	4.53e-05	0.000308	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—breast cancer	4.49e-05	0.000305	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—breast cancer	4.46e-05	0.000303	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—breast cancer	4.44e-05	0.000302	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—breast cancer	4.44e-05	0.000302	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—breast cancer	4.42e-05	0.000301	CcSEcCtD
Carfilzomib—Dizziness—Paclitaxel—breast cancer	4.38e-05	0.000298	CcSEcCtD
Carfilzomib—Cough—Methotrexate—breast cancer	4.32e-05	0.000294	CcSEcCtD
Carfilzomib—Body temperature increased—Capecitabine—breast cancer	4.3e-05	0.000292	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—breast cancer	4.29e-05	0.000291	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—breast cancer	4.22e-05	0.000287	CcSEcCtD
Carfilzomib—Vomiting—Paclitaxel—breast cancer	4.21e-05	0.000286	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—breast cancer	4.15e-05	0.000282	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—breast cancer	4.15e-05	0.000282	CcSEcCtD
Carfilzomib—Headache—Paclitaxel—breast cancer	4.15e-05	0.000282	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—breast cancer	4.13e-05	0.000281	CcSEcCtD
Carfilzomib—Cough—Epirubicin—breast cancer	4.05e-05	0.000275	CcSEcCtD
Carfilzomib—Asthenia—Docetaxel—breast cancer	4.03e-05	0.000274	CcSEcCtD
Carfilzomib—Infection—Methotrexate—breast cancer	4.02e-05	0.000273	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—breast cancer	4e-05	0.000272	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—breast cancer	3.97e-05	0.00027	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—breast cancer	3.96e-05	0.000269	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—breast cancer	3.95e-05	0.000268	CcSEcCtD
Carfilzomib—Nausea—Paclitaxel—breast cancer	3.93e-05	0.000267	CcSEcCtD
Carfilzomib—Asthenia—Capecitabine—breast cancer	3.9e-05	0.000265	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—breast cancer	3.86e-05	0.000262	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—breast cancer	3.84e-05	0.000261	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—breast cancer	3.84e-05	0.000261	CcSEcCtD
Carfilzomib—Infection—Epirubicin—breast cancer	3.76e-05	0.000256	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—breast cancer	3.74e-05	0.000255	CcSEcCtD
Carfilzomib—Diarrhoea—Capecitabine—breast cancer	3.72e-05	0.000253	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—breast cancer	3.71e-05	0.000252	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—breast cancer	3.71e-05	0.000252	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—breast cancer	3.71e-05	0.000252	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—breast cancer	3.69e-05	0.000251	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—breast cancer	3.66e-05	0.000249	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—breast cancer	3.65e-05	0.000248	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—breast cancer	3.61e-05	0.000245	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—breast cancer	3.61e-05	0.000245	CcSEcCtD
Carfilzomib—Dizziness—Capecitabine—breast cancer	3.59e-05	0.000244	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—breast cancer	3.57e-05	0.000243	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—breast cancer	3.52e-05	0.000239	CcSEcCtD
Carfilzomib—Headache—Docetaxel—breast cancer	3.52e-05	0.000239	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—breast cancer	3.49e-05	0.000237	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—breast cancer	3.48e-05	0.000237	CcSEcCtD
Carfilzomib—Pain—Methotrexate—breast cancer	3.46e-05	0.000235	CcSEcCtD
Carfilzomib—Vomiting—Capecitabine—breast cancer	3.45e-05	0.000235	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—breast cancer	3.45e-05	0.000234	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—breast cancer	3.43e-05	0.000233	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—breast cancer	3.42e-05	0.000233	CcSEcCtD
Carfilzomib—Headache—Capecitabine—breast cancer	3.4e-05	0.000231	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—breast cancer	3.37e-05	0.000229	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—breast cancer	3.34e-05	0.000227	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—breast cancer	3.33e-05	0.000227	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—breast cancer	3.29e-05	0.000224	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—breast cancer	3.26e-05	0.000222	CcSEcCtD
Carfilzomib—Pain—Epirubicin—breast cancer	3.24e-05	0.00022	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—breast cancer	3.24e-05	0.00022	CcSEcCtD
Carfilzomib—Nausea—Capecitabine—breast cancer	3.23e-05	0.000219	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—breast cancer	3.2e-05	0.000217	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.19e-05	0.000217	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—breast cancer	3.17e-05	0.000215	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—breast cancer	3.12e-05	0.000212	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—breast cancer	3.04e-05	0.000207	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—breast cancer	3.02e-05	0.000205	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—breast cancer	3e-05	0.000204	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—breast cancer	3e-05	0.000204	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—breast cancer	2.99e-05	0.000203	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—breast cancer	2.9e-05	0.000197	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—breast cancer	2.77e-05	0.000188	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—breast cancer	2.77e-05	0.000188	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—breast cancer	2.72e-05	0.000185	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—breast cancer	2.67e-05	0.000182	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—breast cancer	2.59e-05	0.000176	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—breast cancer	2.57e-05	0.000175	CcSEcCtD
Carfilzomib—Headache—Methotrexate—breast cancer	2.53e-05	0.000172	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—breast cancer	2.51e-05	0.000171	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—breast cancer	2.5e-05	0.00017	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—breast cancer	2.41e-05	0.000164	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—breast cancer	2.4e-05	0.000163	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—breast cancer	2.4e-05	0.000163	CcSEcCtD
Carfilzomib—Headache—Epirubicin—breast cancer	2.37e-05	0.000161	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—breast cancer	2.32e-05	0.000157	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—breast cancer	2.25e-05	0.000153	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—breast cancer	2.23e-05	0.000151	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—breast cancer	2.19e-05	0.000149	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—breast cancer	2.08e-05	0.000141	CcSEcCtD
Carfilzomib—ABCB1—Metabolism—MTR—breast cancer	2.53e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RELA—breast cancer	2.53e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RELA—breast cancer	2.53e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RELA—breast cancer	2.53e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—breast cancer	2.53e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—breast cancer	2.53e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—breast cancer	2.52e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—breast cancer	2.52e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—breast cancer	2.52e-06	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—breast cancer	2.51e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RAF1—breast cancer	2.5e-06	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—breast cancer	2.5e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—breast cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RELA—breast cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—breast cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—breast cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—breast cancer	2.49e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HPGDS—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MTOR—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MTOR—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MTOR—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—breast cancer	2.48e-06	1.66e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HBA1—breast cancer	2.47e-06	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—breast cancer	2.45e-06	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MTOR—breast cancer	2.44e-06	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—breast cancer	2.44e-06	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—breast cancer	2.41e-06	1.62e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTT1—breast cancer	2.41e-06	1.61e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ACHE—breast cancer	2.41e-06	1.61e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—breast cancer	2.4e-06	1.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—breast cancer	2.38e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—breast cancer	2.38e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—breast cancer	2.38e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—breast cancer	2.38e-06	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—breast cancer	2.37e-06	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—breast cancer	2.35e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—breast cancer	2.35e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—breast cancer	2.35e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—breast cancer	2.35e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—breast cancer	2.35e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—breast cancer	2.34e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—breast cancer	2.34e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—breast cancer	2.34e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—breast cancer	2.34e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—breast cancer	2.34e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	2.34e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—breast cancer	2.33e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—breast cancer	2.33e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—breast cancer	2.33e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—breast cancer	2.33e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—breast cancer	2.33e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—breast cancer	2.32e-06	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—breast cancer	2.31e-06	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—breast cancer	2.3e-06	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—breast cancer	2.3e-06	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—breast cancer	2.29e-06	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—breast cancer	2.29e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP17A1—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—breast cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO1—breast cancer	2.25e-06	1.51e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS1—breast cancer	2.25e-06	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—breast cancer	2.25e-06	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—breast cancer	2.24e-06	1.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—breast cancer	2.22e-06	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—breast cancer	2.22e-06	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—breast cancer	2.22e-06	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—breast cancer	2.21e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—breast cancer	2.21e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—breast cancer	2.21e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2D6—breast cancer	2.21e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—breast cancer	2.2e-06	1.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—breast cancer	2.2e-06	1.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—breast cancer	2.2e-06	1.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—breast cancer	2.19e-06	1.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—breast cancer	2.18e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA2—breast cancer	2.17e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—breast cancer	2.17e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—breast cancer	2.17e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—breast cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—breast cancer	2.15e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—breast cancer	2.15e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—breast cancer	2.15e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—breast cancer	2.15e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—breast cancer	2.15e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—breast cancer	2.15e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—breast cancer	2.14e-06	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—breast cancer	2.14e-06	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—breast cancer	2.14e-06	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—breast cancer	2.13e-06	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—breast cancer	2.13e-06	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—breast cancer	2.12e-06	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—breast cancer	2.12e-06	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—breast cancer	2.11e-06	1.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	2.11e-06	1.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FASN—breast cancer	2.11e-06	1.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—BCHE—breast cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK8—breast cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK8—breast cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK8—breast cancer	2.1e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC5A5—breast cancer	2.07e-06	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—breast cancer	2.07e-06	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—breast cancer	2.07e-06	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—breast cancer	2.07e-06	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK8—breast cancer	2.07e-06	1.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—breast cancer	2.04e-06	1.37e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NQO1—breast cancer	2e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A1—breast cancer	2e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—breast cancer	2e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—breast cancer	2e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—breast cancer	2e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—breast cancer	1.99e-06	1.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—breast cancer	1.99e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—breast cancer	1.99e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—breast cancer	1.99e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—breast cancer	1.98e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—breast cancer	1.97e-06	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—breast cancer	1.96e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP3A4—breast cancer	1.95e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—breast cancer	1.95e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—breast cancer	1.94e-06	1.3e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—breast cancer	1.93e-06	1.3e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—breast cancer	1.93e-06	1.3e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—breast cancer	1.93e-06	1.3e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—breast cancer	1.93e-06	1.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—breast cancer	1.92e-06	1.29e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1B1—breast cancer	1.92e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—breast cancer	1.92e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—breast cancer	1.92e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—breast cancer	1.92e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	1.91e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—breast cancer	1.9e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—breast cancer	1.9e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—breast cancer	1.9e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—breast cancer	1.89e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—breast cancer	1.88e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—breast cancer	1.88e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSP90AA1—breast cancer	1.88e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—breast cancer	1.87e-06	1.25e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—breast cancer	1.84e-06	1.24e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—breast cancer	1.84e-06	1.23e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—breast cancer	1.83e-06	1.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—breast cancer	1.83e-06	1.23e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—breast cancer	1.83e-06	1.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA1—breast cancer	1.83e-06	1.23e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—breast cancer	1.81e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—breast cancer	1.81e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—breast cancer	1.81e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—breast cancer	1.8e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STK11—breast cancer	1.8e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP19A1—breast cancer	1.8e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—breast cancer	1.78e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—breast cancer	1.77e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—breast cancer	1.76e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—breast cancer	1.76e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—breast cancer	1.76e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—breast cancer	1.76e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—breast cancer	1.75e-06	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—breast cancer	1.75e-06	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—breast cancer	1.74e-06	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—breast cancer	1.74e-06	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—breast cancer	1.74e-06	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—breast cancer	1.74e-06	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—breast cancer	1.72e-06	1.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—COMT—breast cancer	1.68e-06	1.12e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—breast cancer	1.67e-06	1.12e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMOX1—breast cancer	1.65e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—breast cancer	1.64e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—breast cancer	1.64e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—breast cancer	1.64e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ITPR1—breast cancer	1.64e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—breast cancer	1.63e-06	1.09e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—breast cancer	1.62e-06	1.09e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—breast cancer	1.62e-06	1.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—breast cancer	1.55e-06	1.04e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PLA2G4A—breast cancer	1.53e-06	1.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOR1—breast cancer	1.53e-06	1.03e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—breast cancer	1.53e-06	1.03e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—breast cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—breast cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—breast cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—breast cancer	1.49e-06	9.98e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—breast cancer	1.48e-06	9.89e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—breast cancer	1.48e-06	9.89e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—breast cancer	1.48e-06	9.89e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—breast cancer	1.47e-06	9.83e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—breast cancer	1.46e-06	9.79e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—breast cancer	1.46e-06	9.79e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—breast cancer	1.46e-06	9.79e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—breast cancer	1.46e-06	9.75e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A1—breast cancer	1.45e-06	9.73e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—breast cancer	1.44e-06	9.66e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ERCC2—breast cancer	1.44e-06	9.65e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—breast cancer	1.4e-06	9.37e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—breast cancer	1.4e-06	9.37e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—breast cancer	1.4e-06	9.37e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—breast cancer	1.38e-06	9.23e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—breast cancer	1.35e-06	9.08e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—breast cancer	1.34e-06	8.96e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—breast cancer	1.34e-06	8.96e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—breast cancer	1.34e-06	8.96e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—breast cancer	1.32e-06	8.84e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAV1—breast cancer	1.25e-06	8.37e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—breast cancer	1.23e-06	8.27e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—breast cancer	1.23e-06	8.27e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—breast cancer	1.23e-06	8.27e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—breast cancer	1.22e-06	8.15e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—breast cancer	1.14e-06	7.63e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—breast cancer	1e-06	6.7e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—breast cancer	9.88e-07	6.62e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—breast cancer	9.45e-07	6.33e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—breast cancer	8.72e-07	5.84e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—breast cancer	8.64e-07	5.79e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—breast cancer	7.54e-07	5.05e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—breast cancer	5.32e-07	3.56e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—breast cancer	4.34e-07	2.91e-06	CbGpPWpGaD
